Luca Zammataro at Yale University

University	Yale University
Position	MD PhD Associate Research Scientist
Citations(all)	4420
Citations(since 2020)	2197
Cited By	3062
hIndex(all)	32
hIndex(since 2020)	27
i10Index(all)	49
i10Index(since 2020)	46
Email	Access Email
University Profile Page	Yale University
Google Scholar	View Google Scholar Profile

Erratum to: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function (Nature,(2003), 424, 6947,(391-397), 10.1038/nature01784)

Nature

2024/3/7

Guido Serini

H-Index: 25

Luca Zammataro

H-Index: 20

Luca Primo

H-Index: 23

Luca Tamagnone

H-Index: 34

Masahiko Taniguchi

H-Index: 19

Federico Bussolino

H-Index: 37

Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Nature

2024/2/21

Guido Serini

H-Index: 25

Luca Zammataro

H-Index: 20

Luca Primo

H-Index: 23

Luca Tamagnone

H-Index: 34

Masahiko Taniguchi

H-Index: 19

Federico Bussolino

H-Index: 37

EP007/# 994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma

2022/12/1

Luca Zammataro

H-Index: 20

Levent Mutlu

H-Index: 8

Gary Altwerger

H-Index: 14

BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)

Gynecologic Oncology

2022/8/1

Levent Mutlu

H-Index: 8

Gary Altwerger

H-Index: 14

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate …

Gynecologic Oncology

2022/7/1

Jungmin Choi

H-Index: 19

Levent Mutlu

H-Index: 8

Kevin Yang

H-Index: 4

Gary Altwerger

H-Index: 14

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer

2022/3/15

Natalia Buza

H-Index: 23

Luca Zammataro

H-Index: 20

Burak Zeybek

H-Index: 14

Gary Altwerger

H-Index: 14

Akiko Iwasaki

H-Index: 65

Yong Kong

H-Index: 18

Eric Song

H-Index: 24

Jungmin Choi

H-Index: 19

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types

Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease

2022/2/1

Elisabetta Grillo

H-Index: 9

Michela Corsini

H-Index: 4

Luca Zammataro

H-Index: 20

Stefania Mitola

H-Index: 23

Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants

2021/12/1

Elisabetta Grillo

H-Index: 9

Michela Corsini

H-Index: 4

Luca Zammataro

H-Index: 20

Stefania Mitola

H-Index: 23

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

Gynecologic oncology

2021/11/1

Burak Zeybek

H-Index: 14

Luca Zammataro

H-Index: 20

Natalia Buza

H-Index: 23

Gary Altwerger

H-Index: 14

In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

Gynecologic Oncology

2021/8/1

Luca Zammataro

H-Index: 20

Burak Zeybek

H-Index: 14

Gary Altwerger

H-Index: 14

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics …

Annals of Oncology

2021/8/1

P Hui

H-Index: 29

S Zaidi

H-Index: 2

Molecular Learning of a Soft-Disks Fluid

2021/7/24

Luca Zammataro

H-Index: 20

Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence

Cancer Letters

2021/6/1

Elisabetta Grillo

H-Index: 9

Michela Corsini

H-Index: 4

Luca Zammataro

H-Index: 20

Andrea Morandi

H-Index: 22

Stefania Mitola

H-Index: 23

Inactive VEGFR2 (R1032Q) exerts pro‐oncogenic activity through heterodimerization with wild‐type receptor

The FASEB Journal

2021/5

Elisabetta Grillo

H-Index: 9

Michela Corsini

H-Index: 4

Luca Zammataro

H-Index: 20

Stefania Mitola

H-Index: 23

Integrated mutational landscape analysis of uterine leiomyosarcomas

Proceedings of the National Academy of Sciences

2021/4/13

Jungmin Choi

H-Index: 19

Luca Zammataro

H-Index: 20

Xiaotong Yao

H-Index: 9

Aditya Deshpande

H-Index: 7

Burak Zeybek

H-Index: 14

Gary Altwerger

H-Index: 14

Siming Zhao

H-Index: 3

Natalia Buza

H-Index: 23

Antonella Ravaggi

H-Index: 24

Laura Zanotti

H-Index: 17

Franco Odicino

H-Index: 26

Sergio Pecorelli

H-Index: 46

Marcin Imielinski

H-Index: 42

Joseph Schlessinger

H-Index: 70

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

Oncogene

2021/4/8

Mark Schroeder

H-Index: 27

Jia Yu

H-Index: 1

Luca Zammataro

H-Index: 20

Lorenzo Malatino

H-Index: 30

A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and …

Cancer Letters

2021/1/1

Elisabetta Grillo

H-Index: 9

Michela Corsini

H-Index: 4

Luca Zammataro

H-Index: 20

Stefania Mitola

H-Index: 23

The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas

Gynecologic Oncology

2020/10/1

Luca Zammataro

H-Index: 20

Burak Zeybek

H-Index: 14

Gary Altwerger

H-Index: 14

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic oncology

2020/9/1

Luca Zammataro

H-Index: 20

Burak Zeybek

H-Index: 14

Gary Altwerger

H-Index: 14

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial …

Molecular oncology

2020/3

Luca Zammataro

H-Index: 20

Anna Bianchi

H-Index: 1

Burak Zeybek

H-Index: 14

Natalia Buza

H-Index: 23

Gary Altwerger

H-Index: 14

Luca Zammataro

Yale University

About Luca Zammataro

Luca Zammataro Information

Luca Zammataro Skills & Research Interests

Top articles of Luca Zammataro

Erratum to: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function (Nature,(2003), 424, 6947,(391-397), 10.1038/nature01784)

Guido Serini

Luca Zammataro

Luca Primo

Luca Tamagnone

Masahiko Taniguchi

Federico Bussolino

Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Guido Serini

Luca Zammataro

Luca Primo

Luca Tamagnone

Masahiko Taniguchi

Federico Bussolino

EP007/# 994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma

Luca Zammataro

Levent Mutlu

Gary Altwerger

BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)

Levent Mutlu

Gary Altwerger

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate …

Jungmin Choi

Levent Mutlu

Kevin Yang

Gary Altwerger

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Natalia Buza

Luca Zammataro

Burak Zeybek

Gary Altwerger

Akiko Iwasaki

Yong Kong

Eric Song

Jungmin Choi

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types

Elisabetta Grillo

Michela Corsini

Luca Zammataro

Stefania Mitola

Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants

Elisabetta Grillo

Michela Corsini

Luca Zammataro

Stefania Mitola

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

Burak Zeybek

Luca Zammataro

Natalia Buza

Gary Altwerger

In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

Luca Zammataro

Burak Zeybek

Gary Altwerger

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics …

P Hui

S Zaidi

Molecular Learning of a Soft-Disks Fluid

Luca Zammataro

Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence

Elisabetta Grillo

Michela Corsini

Luca Zammataro

Andrea Morandi

Stefania Mitola

Inactive VEGFR2 (R1032Q) exerts pro‐oncogenic activity through heterodimerization with wild‐type receptor

Elisabetta Grillo

Michela Corsini

Luca Zammataro

Stefania Mitola

Integrated mutational landscape analysis of uterine leiomyosarcomas

Jungmin Choi

Luca Zammataro

Xiaotong Yao